- Conditions
- Liver Dysfunction, Healthy
- Interventions
- Lepodisiran
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
Eli Lilly and Company clinical trials
Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Live official records
Open in full search- Conditions
- Plaque Psoriasis
- Interventions
- LY4100511, Placebo
- Drug
- Lead sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Bryant, Arkansas • Beverly Hills, California + 12 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Ramucirumab, Pembrolizumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib, Ibrutinib
- Drug
- Lead sponsor
- Loxo Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 737 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 19
- States / cities
- Anaheim, California • Cerritos, California • Palo Alto, California + 15 more
- Conditions
- Gaucher Disease, Gaucher Disease, Type 1
- Interventions
- LY3884961
- Genetic
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Fairfax, Virginia
- Conditions
- Obesity, Overweight, Overweight or Obesity
- Interventions
- Orforglipron, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 43
- States / cities
- Chandler, Arizona • Sun City West, Arizona • Concord, California + 37 more
- Conditions
- Non Small Cell Lung Cancer, Metastatic, Recurrent
- Interventions
- Lorlatinib, Ramucirumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
- Conditions
- Migraine
- Interventions
- Galcanezumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Covid19, Corona Virus Infection
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Detroit, Michigan • Cleveland, Ohio
- Conditions
- Crohn's Disease
- Interventions
- Mirikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 54
- States / cities
- Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
- Conditions
- Desmoplastic Small Round Cell Tumor
- Interventions
- Ramucirumab, Cyclophosphamide, Vinorelbine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Months to 29 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
About this Eli Lilly and Company sponsor directory page
- What this page lists
- U.S. ClinicalTrials.gov public records where Eli Lilly and Company is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Eli Lilly and Company trials.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.
Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Eli Lilly and Company.